10x Genomics Analyst Price Targets - Benzinga

10x Genomics Inc

TXGNASDAQ

Trade with Public

Trade with Public

$61.00

-0.54-0.88%

마지막 업데이트: Aug 31, 9:25 AM

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 비교 옵션 주식 보고서

10x Genomics Analyst Price Targets

Wall Street analyst price targets and consensus rating for 10x Genomics (TXG).

Price Target Range — 13 Quarters

Analyst Consensus — 16 Analysts

6Buy

9Hold

1Sell

Consensus RatingNeutral# Analysts16Avg. Consensus PT$33Upside to Avg. PT-45.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 12, 2026	Stephens & Co.	Mason Carrico	PT Raise	Overweight	$50→$65
Aug 10, 2026	Piper Sandler	David Westenberg	PT Raise	Neutral	$42→$47
Aug 10, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Buy	$50→$60
Aug 7, 2026	Citigroup	Brendan Digan	PT Raise	Neutral	$45→$50
Aug 7, 2026	Morgan Stanley	Tejas Savant	PT Raise	Equal-Weight	$37→$40
Jul 17, 2026	Leerink Partners	Mike Kratky	PT Raise	Market Perform	$23→$40
Jul 14, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Buy	$32→$50
Jul 9, 2026	Morgan Stanley	Tejas Savant	PT Raise	Equal-Weight	$22→$37
Jul 8, 2026	Citigroup	Patrick Donnelly	PT Raise	Neutral	$24→$45
Jul 1, 2026	Piper Sandler	David Westenberg	PT Raise	Neutral	$20→$42
Jun 24, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$30→$40
May 12, 2026	Morgan Stanley	Tejas Savant	PT Raise	Equal-Weight	$20→$22
May 12, 2026	JP Morgan	Casey Woodring	PT Raise	Neutral	$17→$20
Apr 20, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Buy	$22→$32
Apr 20, 2026	B of A Securities	Derik De Bruin	PT Raise	Neutral	$21→$30
Apr 14, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$22→$30
Apr 7, 2026	Citigroup	Patrick Donnelly	PT Raise	Neutral	$18→$24
Mar 31, 2026	William Blair	Matt Larew	Upgrade	Market Perform→Outperform	—
Mar 2, 2026	Stifel	Daniel Arias	PT Raise	Buy	$20→$25
Feb 20, 2026	UBS	Dan Leonard	PT Raise	Neutral	$14→$20

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Stephens & Co. Maintains Overweight on 10x Genomics, Raises Price Target to $65

Stephens & Co. analyst Mason Carrico maintains 10x Genomics (NASDAQ:TXG) with a Overweight and raises the price target from $50 to $65.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $47

Piper Sandler analyst David Westenberg maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $42 to $47.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on 10x Genomics, Raises Price Target to $60

Canaccord Genuity analyst Kyle Mikson maintains 10x Genomics (NASDAQ:TXG) with a Buy and raises the price target from $50 to $60.

Benzinga Newsdesk

PRO
Citigroup Maintains Neutral on 10x Genomics, Raises Price Target to $50

Citigroup analyst Brendan Digan maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $45 to $50.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on 10x Genomics, Raises Price Target to $40

Morgan Stanley analyst Tejas Savant maintains 10x Genomics (NASDAQ:TXG) with a Equal-Weight and raises the price target from $37 to $40.

Benzinga Newsdesk

PRO
Leerink Partners Maintains Market Perform on 10x Genomics, Raises Price Target to $40

Leerink Partners analyst Mike Kratky maintains 10x Genomics (NASDAQ:TXG) with a Market Perform and raises the price target from $23 to $40.

Benzinga Newsdesk